Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


engeneOS Inc.

Latest From engeneOS Inc.

The Climate for Investing in Platform Technologies

The founder and CEO of Flagship Ventures, Noubar Afeyan, points to several reasons why early-stage investing should be on the upswing.

BioPharmaceutical Strategy

Compound Therapeutics Inc.

Compound Therapeutics has engineered proteins, called Adzymes, which bind to targets with the specificity of antibodies but unlike them destroy their targets using an attached enzyme.


Start-Up Previews (2/02)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Small Size=Big Potential , features profiles of C Sixty Inc., engeneOS Inc., Nanospectra Biosciences Inc. and Oxonica Ltd., Plus these Selected Start-Ups across Health Care: Addiction Therapies Inc., ImpactRx Inc., Ingenium Pharmaceuticals AG and Insulet Corp.

EngeneOS Inc.

Boston-area start-up engeneOS Inc. aspires to build molecular machines with starting materials that come from nature. The firm aims to take advantage of the the fact that proteins and nucleic acids have evolved highly specific capabilities over thousands of years. Management sees them as components that can be catalogued, combined and harnessed to carry out new tasks.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals